Nuzenio

Arpi

Arpi news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 8 publisher sources 100/100 entity strength

Latest news

FDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer - OncodailyOncodaily · Wed, 05 Aug 2026 10:28:25 GMTReal-World Survival Benefit of ADT plus ARPI in Frail Veterans with mHSPC - Martin Schoen - UroTodayUroToday · Mon, 03 Aug 2026 21:29:56 GMTPluvicto Approved Earlier in Metastatic Prostate Cancer - MedscapeMedscape · Mon, 03 Aug 2026 14:03:57 GMTFDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI for Prostate Cancer - Oncology News CentralOncology News Central · Mon, 03 Aug 2026 10:27:38 GMTFDA Expands Approval of Pluvicto in Combination with ARPI for PSMA-Positive mAPMN/S Prostate Cancer - diagnosticimaging.comdiagnosticimaging.com · Sat, 01 Aug 2026 13:16:50 GMTFDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer - Targeted OncologyTargeted Oncology · Fri, 31 Jul 2026 21:11:29 GMTThe DE-ESCALATE Trial of Intermittent ADT and ARPI in Metastatic Hormone-Sensitive Prostate Cancer - Fabio Turco - UroTodayUroToday · Fri, 31 Jul 2026 20:30:33 GMTManaging ARPI Toxicities and Treatment Goals in mCSPC - Urology TimesUrology Times · Mon, 27 Jul 2026 07:00:00 GMT

Timeline

Wed, 05 Aug 2026 10:28:25 GMTFDA Approved Pluvicto Plus ARPI for PSMA-Positive mAPMN/S Prostate Cancer - Oncodaily
Mon, 03 Aug 2026 21:29:56 GMTReal-World Survival Benefit of ADT plus ARPI in Frail Veterans with mHSPC - Martin Schoen - UroToday
Mon, 03 Aug 2026 14:03:57 GMTPluvicto Approved Earlier in Metastatic Prostate Cancer - Medscape
Mon, 03 Aug 2026 10:27:38 GMTFDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI for Prostate Cancer - Oncology News Central
Sat, 01 Aug 2026 13:16:50 GMTFDA Expands Approval of Pluvicto in Combination with ARPI for PSMA-Positive mAPMN/S Prostate Cancer - diagnosticimaging.com
Fri, 31 Jul 2026 21:11:29 GMTFDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer - Targeted Oncology

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Arpi.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.